For the quarter ended September 2026, Alamar Biosciences (ALMR Quick QuoteALMR - Free Report) reported revenue of $33.55 million, representing no change compared to the same period last year. EPS came in at -$0.19, compared to $0 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $30.13 million, representing a surprise of +11.35%. The company delivered an EPS surprise of +13.64%, with the consensus EPS estimate being -$0.22.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Alamar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Consumables: $17.83 million compared to the $16.98 million average estimate based on two analysts.
• Service and other revenue: $7.25 million compared to the $4.78 million average estimate based on two analysts.
• Product revenue: $26.3 million versus $25.34 million estimated by two analysts on average.
• Revenue- Instruments: $8.47 million versus $8.36 million estimated by two analysts on average.

View all Key Company Metrics for Alamar here>>>

Shares of Alamar have returned -24.1% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.